Price Alert

Translational Development... (TDACU)

NASDAQ: TDACU · Real-Time Price · USD

10.36

0.00 (0.00%)

At close: Aug 20, 2025, 3:59 PM

Translational Development Acquisition Statistics

Share Statistics

Translational Development Acquisition has n/a shares outstanding. The number of shares has increased by -33.4% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	-33.4%
Shares Change (QoQ)	15.27%
Owned by Institutions (%)	n/a
Shares Floating	2.87M
Failed to Deliver (FTD) Shares	1,445
FTD / Avg. Volume	211.57%

Short Selling Information

The latest short interest is 30, so 0% of the outstanding shares have been sold short.

Short Interest	30
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1

Valuation Ratios

The PE ratio is -570.9 and the forward PE ratio is null. Translational Development Acquisition's PEG ratio is 6.6.

PE Ratio	-570.9
Forward PE	n/a
PS Ratio	0
Forward PS	n/a
PB Ratio	0.24
P/FCF Ratio	-47.61
PEG Ratio	6.6

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Translational Development Acquisition.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.09, with a Debt / Equity ratio of 36211.42.

Current Ratio	3.09
Quick Ratio	3.09
Debt / Equity	36211.42
Debt / EBITDA	-86.06M
Debt / FCF	-7.18M
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	undefined
Asset Turnover	6090.2
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is 0.09, so Translational Development Acquisition's price volatility has been higher than the market average.

Beta	0.09
52-Week Price Change	n/a
50-Day Moving Average	10.39
200-Day Moving Average	n/a
Relative Strength Index (RSI)	39.16
Average Volume (20 Days)	683

Income Statement

In the last 12 months, Translational Development Acquisition had revenue of 1,065.8B and earned -71.01K in profits. Earnings per share was -0.02.

Revenue	1,065.8B
Gross Profit	744.92B
Operating Income	-196.36K
Net Income	-71.01K
EBITDA	-71.01K
EBIT	-71.01K
Earnings Per Share (EPS)	-0.02

Full Income Statement

Balance Sheet

The company has 438.17K in cash and 6,110.8B in debt, giving a net cash position of -6,110.8B.

Cash & Cash Equivalents	438.17K
Total Debt	6,110.8B
Net Cash	-6,110.8B
Retained Earnings	-5.6M
Total Assets	178.18M
Working Capital	-128.6K

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -851.45K and capital expenditures -4, giving a free cash flow of -851.45K.

Operating Cash Flow	-851.45K
Capital Expenditures	-4
Free Cash Flow	-851.45K
FCF Per Share	-0.21

Full Cash Flow Statement

Margins

Gross margin is 69.89%, with operating and profit margins of 0% and 0%.

Gross Margin	69.89%
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TDACU does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for TDACU.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	106783.8
Piotroski F-Score	2